Codexis Newswire

Codexis Newswire

Comprehensive Real-Time News Feed for Codexis.

Results 1 - 20 of 72 in Codexis

  1. Nantahala Capital Management LLC Has $15,595,000 Position in Codexis Inc.Read the original story w/Photo

    16 hrs ago | Daily Political

    Nantahala Capital Management LLC boosted its stake in shares of Codexis Inc. by 4.2% during the first quarter, Holdings Channel reports. The institutional investor owned 5,014,509 shares of the company's stock after buying an additional 203,287 shares during the period.

    Comment?

  2. Codexis Inc. (CDXS) Downgraded by Zacks Investment Research to SellRead the original story w/Photo

    Tuesday Jul 19 | Daily Political

    According to Zacks, "Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis' proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing.

    Comment?

  3. Codexis Inc. (CDXS) Downgraded by Zacks Investment ResearchRead the original story w/Photo

    Monday Jul 18 | AmericanBankingNews.com

    According to Zacks, "Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis' proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing.

    Comment?

  4. Codexis Inc. (CDXS) Stock Rating Lowered by Zacks Investment ResearchRead the original story w/Photo

    Monday Jul 18 | AmericanBankingNews.com

    According to Zacks, "Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis' proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing.

    Comment?

  5. Q2 2016 EPS Estimates for Codexis Inc. (CDXS) Lifted by AnalystRead the original story w/Photo

    Sunday Jul 17 | AmericanBankingNews.com

    Investment analysts at First Analysis upped their Q2 2016 earnings estimates for Codexis in a research note issued to investors on Thursday. First Analysis analyst now forecasts that the brokerage will earn $0.06 per share for the quarter, up from their previous forecast of .

    Comment?

  6. Codexis Inc. (CDXS) Short Interest UpdateRead the original story w/Photo

    Friday Jul 15 | AmericanBankingNews.com

    Codexis Inc. was the target of a significant increase in short interest in June. As of June 30th, there was short interest totalling 1,897,381 shares, an increase of 263.1% from the June 15th total of 522,540 shares.

    Comment?

  7. Codexis Inc. (CDXS) Trading Down 4.9%Read the original story w/Photo

    Wednesday Jul 13 | Daily Political

    Shares of Codexis Inc. fell 4.9% on Wednesday . The stock traded as low as $4.07 and last traded at $4.07, with a volume of 73,117 shares changing hands.

    Comment?

  8. Latest Trend and Development in Global Starch and Sugar Enzyme for Alcohol Industry 2016Read the original story

    Tuesday Jul 12 | Emailwire.com

    Researchmoz added Most up-to-date research on " Global Starch and Sugar Enzyme for Alcohol Market" to its huge collection of research reports. To Get Sample Copy of Report visit @ This report mainly covers the following Segment regions including North America Europe Japan China Southeast Asia India Browse Detail Report With TOC @ The players list Dupont Amano Enzyme Dyadic International Codexis Advanced Enzyme Technology The Soufflet Group Roquette Novozymes Lesaffre ABF With 10 top producers.

    Comment?

  9. Codexis Inc. (CDXS) Trading Up 2.5%Read the original story w/Photo

    Saturday Jul 9 | Daily Political

    Shares of Codexis Inc. were up 2.5% during trading on Thursday . The company traded as high as $4.15 and last traded at $4.12, with a volume of 87,317 shares.

    Comment?

  10. Analysts Expect Codexis Inc. (NASDAQ:CDXS) to Announce ($0.03) EPSRead the original story w/Photo

    Thursday Jul 7 | Daily Political

    Codexis Inc. has received an average broker rating score of 1.67 from the three analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and two have issued a strong buy rating on the company.

    Comment?

  11. Codexis Inc. (NASDAQ:CDXS) Given $6.00 Average Price Target by BrokeragesRead the original story w/Photo

    Tuesday Jul 5 | AmericanBankingNews.com

    Shares of Codexis Inc. have been assigned an average broker rating score of 1.67 from the three analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company.

    Comment?

  12. Zacks: Analysts Set $6.00 Price Target for Codexis, Inc.Read the original story w/Photo

    Jun 13, 2016 | Daily Political

    Codexis, Inc. has received a consensus broker rating score of 1.67 from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company.

    Comment?

  13. Industrial Enzymes Market To Gain From Enhanced Usage In Food &...Read the original story w/Photo

    Jun 6, 2016 | GlobeNewswire

    ... British Foods PLC E. I. Du Pont De Nemours and Company Adisseo France SaS, Dyadic International Incorporated CHR, Codexis Incorporated. Hansen Holding A/S, and Amano Enzyme Incorporated. Grand View Research, Inc. is a U.S. based market research and ...

    Comment?

  14. Codexis, Inc. (CDXS) Earns Buy Rating from Analysts at HC WainwrightRead the original story w/Photo

    Jun 2, 2016 | AmericanBankingNews.com

    ... a potential upside of 56.25% from the stock's current price. Separately, Zacks Investment Research downgraded Codexis from a "hold" rating to a "sell" rating in a research report on Tuesday, May 10th. Other institutional investors recently bought ...

    Comment?

  15. Codexis to Present at Upcoming Investment ConferencesRead the original story

    May 18, 2016 | PressReleasePoint

    REDWOOD CITY, Calif., May 18, 2016 -- Codexis, Inc. , a leading protein engineering company, announces that management will present at two upcoming investment conferences: 17th Annual B. Riley Investor Conference on May 25, 2016, at 9:30 a.m. Pacific time . The conference is being held at the Loews Hollywood Hotel in Los Angeles.

    Comment?

  16. HC Wainwright Reaffirms Buy Rating for Codexis, Inc.Read the original story w/Photo

    May 15, 2016 | AmericanBankingNews.com

    ... institutional investors have recently bought and sold shares of the stock. Menta Capital LLC raised its position in Codexis by 1.5% in the first quarter. Menta Capital LLC now owns 41,378 shares of the company's stock worth $129,000 after buying an ...

    Comment?

  17. Codexis, Inc. (CDXS) to Post Q2 2016 Earnings of $0.02 Per Share, Craig Hallum ForecastsRead the original story w/Photo

    May 13, 2016 | Daily Political

    Craig Hallum increased their Q2 2016 EPS estimates for shares of Codexis in a note issued to investors on Tuesday, according to Zacks Investment Research . Craig Hallum analyst M. Tiampo now expects that the brokerage will earn $0.02 per share for the quarter, up from their prior estimate of .

    Comment?

  18. HC Wainwright Reaffirms "Buy" Rating for Codexis, Inc.Read the original story w/Photo

    May 10, 2016 | Daily Political

    's stock had its "buy" rating restated by analysts at HC Wainwright in a note issued to investors on Tuesday, Market Beat.com reports. Codexis opened at 3.27 on Tuesday.

    Comment?

  19. Codexis, Inc. (CDXS) Stock Rating Lowered by Zacks Investment ResearchRead the original story w/Photo

    May 10, 2016 | AmericanBankingNews.com

    According to Zacks, "Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis' proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing.

    Comment?

  20. Codexis, Inc. (CDXS) Downgraded by Zacks Investment Research to SellRead the original story w/Photo

    May 10, 2016 | AmericanBankingNews.com

    According to Zacks, "Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis' proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing.

    Comment?